Abstract: Vincristine has been in clinical use for over 50 years and is indicated in the treatment of a wide range of adult and pediatric malignancies, most commonly in combination therapy. Dose-limiting toxicities of vincristine arise primarily in the peripheral nervous system with central nervous system toxicity generally not observed with intravenous therapy due to poor penetration of the blood brain barrier. Unintentional administration of vincristine directly into the cerebrospinal fluid (CSF) produces profound neurotoxicity. Since the first report in 1968 there have been numerous other cases with 31 (18 in children) of these published in the literature with 25 (15 in children) resulting in death. Many other cases are believed to have occurred but have not been officially reported. Fatalities appeared due to a progressive ascending myeloencephalopathy. Early recognition and immediate treatment with CSF drainage and intrathecal exchange appears to be the only intervention that has improved patient survival. Guidelines for the prevention of this horrific medication error have been proposed. All errors involving the administration of a vinca alkaloid into the CSF over the past 45 years have occurred when the drug has been prepared in a syringe. The most effective method currently available for preventing this tragic and invariably fatal event from ever happening is to abolish the syringe as a method of vincrisine administration. This method must be replaced by administration via a small-volume intravenous bag for all patients. Concerns regarding an increased risk of extravasation with the use of mini-bags, particularly in the pediatric population, are unfounded and should not be a deterrent to implementing this strategy. The consequences of inadvertent intrathecal administration of vincristine are overwhelming. The optimum strategy for managing this problem is by developing effective methods of prevention and incorporating these proposals into pediatric oncology centers internationally.
INTRODUCTION
Vincristine is a naturally occurring alkaloid obtained from the leaves of the periwinkle plant (Catharanthus roseus), which has been in clinical use for over 50 years [1] . Vincristine has been indicated in the management of a wide range of pediatric and adult malignancies in the first or second-line setting, most commonly in combination therapy. Current pediatric indications include acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, sarcomas, Wilm's tumour and neuroblastoma.
The primary mechanism by which vincristine inhibits tumour growth appears to be through interference with mitotic spindle function. It binds to tubulin to block polymerization into microtubules thereby inhibiting mitotis in metaphase [1] . Vincristine is unique among chemotherapeutic agents in that dose-limiting toxicities are largely restricted to the peripheral nervous system. Cellulitis with tissue necrosis frequently develops following accidental extravasation. Alopecia has been reported but varies with dose and duration of therapy. Hematological toxicities are rarely seen [1] .
Vincristine-induced neurotoxicity is caused by interference with microtubule function resulting in blockage of axonal transport and hence axonal degeneration [1] . Factors affecting the incidence and severity of neuropathy include: age (with infants and the elderly most affected), total dose and duration of therapy, impaired biliary excretion, concomitant neurotoxic medications and other pre-existing neuropathies. Drug interactions have also been linked to increased vincristine neurotoxicity. Drugs implicated include azole antifungals, cyclosporine, isoniazid and nifedipine [2, 3] .
Peripheral neuropathy occurs frequently with the earliest manifestation being suppression of the Achilles tendon reflex, followed by paresthesia involving the hands and feet [4] . Muscle pain, weakness and sensory impairment can develop if the drug is continued. Recovery usually begins with cessation of vincristine, however minor symptoms, such as numbness and tingling of fingers and toes, may continue for several months or longer. Effects on the autonomic nervous system include urinary dysfunction, gastrointestinal symptoms (constipation, abdominal pain and paralytic ileus), impotence and orthostatic hypotension [4] . Cranial nerve abnormalities, including ptosis, diplopia, facial weakness, jaw pain and hoarseness of the voice, can present. Symptoms of cerebral involvement can occasionally occur and include agitation, depression, insomnia, hallucinations and seizures.
Due to poor penetration of the blood brain barrier, central nervous system (CNS) toxicity is generally not seen following the intravenous (IV) administration of therapeutic doses of vincristine. CNS concentrations of vincristine in 17 pediatric patients receiving bolus IV vincristine during treatment for acute lymphoblastic leukaemia or non-Hodgkin's lymphoma were tested [5] . No detectable vincristine concentrations were measured in samples taken from the cerebrospinal fluid (CSF). A number of cases of accidental vincristine overdose, often resulting in death, have been reported [6] [7] [8] [9] [10] .
ACCIDENTAL INTRATHECAL ADMINISTRATION OF VINCRISTINE
Administration of vincristine directly into the CSF has been associated with catastrophic neurotoxicity. Since the first case in 1968 [11] , numerous reports of accidental administration of vincristine into the CSF have been documented in the literature. Unfortunately, many other cases have not been published or officially reported. There is detail available, though often limited, on 31 reported cases of accidental intrathecal vincristine administration [12] [13] [14] . Of these 25 have resulted in fatalities. In children, 18 cases have been published with 15 deaths (see Table 1 ) [11, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . Ages have ranged from 15 months to 18 years. A fatal outcome has occurred even when the mistake has been detected during the actual process of administration with only a fraction of the dose given intrathecally [31] . Vincristine has been shown to bind to tubulin in less than 5 minutes, so any intervention, however rapid, has a low chance of success [32] .
Length of survival in pediatric patients following administration of vincristine into the CSF varied from 3 to 83 days. Of the three non-lethal cases, all were alive at last report [20, 21, 23] . At 24 months post vincristine, one was a quadriplegic requiring nocturnal mechanical ventilation [20] ; at 18 months, the second had paraplegia of the lower limbs, was fecally incontinent and required urinary catheterization [21] ; and at 34 months, the third suffered hypotonia and areflexia of the lower limbs with mild impairment of all sensory modalities [23] .
Autopsies were performed in a several cases, and details of findings are available from the individual case reports [11, 16, 18, 23, 25, 26, 28] . The CNS lesions described are those of an ascending chemical leptomeningitis and ventriculitis with marked involvement of the aqueduct and III and IV ventricles [23] . Underlying this is a necrotizing process involving the spinal cord, brain stem and cerebellum. Fatalities appeared due to a progressive ascending myeloencephalopathy.
Manifestations included meningism, sensory and motor dysfunction, urinary retention, weakness, lethargy, confusion, fluctuating levels of consciousness, paralysis, respiratory failure and coma.
In 2007, large scale contamination occurred at a Chinese factory run by the Shanghai Pharmaceutical Group [33] . During the commercial manufacturing process, methotrexate and cytarabine, drugs that are commonly given by the intrathecal route, were contaminated by trace amounts of vincristine. The plant was closed and these drugs recalled by the Chinese Government. This incident was believed to have led to 193 patients, including many children, nationwide being administered vincristine unintentionally as part of their normal intrathecal medication plans. Paralysis was common. Table  1 . Early recognition and immediate treatment with drainage of the CSF and intrathecal exchange seems to be the only intervention that has had any impact on patient survival.
MANAGEMENT

Management of individual cases is set out in
In 13 of the pediatric cases, the error was recognised within 30 minutes. In the three children who survived, the mistake was noticed immediately. Removal of vincristine from the CNS has been attempted in the majority of cases. No attempt to remove CNS was made in one patient [17] and details of management weren't explained in several other cases [16, 24, 25, 30] . In the initial case, Schochet exchanged 200 ml of CNS with 0.9% sodium chloride in 10 ml aliquots over the first 24 hours following vincristine administration [11] . Gaidys washed out the CNS with 500ml of 0.9% sodium chloride over 90 minutes but this didn't start until over four hours following the initial error [17] . Dyke was the first to employ a more aggressive form of management using CSF lavage in an adult with Burkitt's lymphoma [34] . This comprised aspiration of the CSF followed by a 24 hour washout using exchange of lactated Ringer's solution and fresh frozen plasma. Since then, a number of cases have been managed with a similar approach [20-23, 28, 30] .
Besides removal of the toxin, lavage seems to have the additional benefit of reducing the vincristine concentration present in the CSF [23] . The volume of injection, dose and length of time from the incident until the ventriculolumbar washout all appear to be critical as these factors may contribute to the extent of drug dispersal within the CNS [28] . The distribution of lesions seen on autopsy suggests damage from a toxin following the course of the CSF [23] , which prompt and aggressive management may be able to alleviate.
Several antidotes for vincristine have been proposed, however none have shown any clinical benefit. Folinic acid, based on a supposed protective effect on mice, was tried following an overdose of IV vincristine [35] . This was believed to have shortened the course of adverse effects and led to a more rapid recovery than previously noted. The neurotoxic effects of 18 patients, given vincristine 1 mg/m 2 IV weekly for 6 weeks in conjunction with oral folinic acid 800 mg daily for 6 weeks, were compared with 70 historical controls who had previously received vincristine only [36] . No protective benefit was observed. Folinic acid was also tried in a number of pediatric cases with no apparent beneficial effects seen [17, 18, [19] [20] [21] [22] 30] .
A randomized, prospective, double-blind, placebocontrolled trial evaluated glutamic acid as a potential modifier of vincristine toxicity, with 84 patients received vincristine 1 mg/m 2 IV weekly for 6 weeks [37] . Half took oral glutamic acid 500 mg three times a day and the others placebo. Signs and symptoms of neurotoxicity were reduced by approximately 50% in the treatment group. In a similarly designed pediatric study, 54 patients received glutamic acid 1500 mg orally daily in 3 divided doses during the 4-week induction with vincristine at a dose of 1.5 mg/m 2 IV weekly [38] . The control group of 40 children received placebo. The onset of neurotoxicity was significantly earlier in the placebo group compared to the glutamic acid group in regards Achilles tendon reflex, patella reflex, parasthesia, and increased frequency of constipation. Six cases utilised glutamic acid as part of their treatment, including all three children who survived [20-23, 28, 30] . The real value of glutamic acid is difficult to judge as all patients were treated with CNS washout and exchange.
A preliminary experimental study conducted in rabbits, showed hypochlorous acid to be of potential benefit in reducing vincristine neurotoxicity following intrathecal administration [39] . Further studies are needed before clinical application can be suggested. Other strategies, including corticosteroids, pyridoxine, vitamin B12, thiamine and caffeine, have been tried but are largely empirical and of questionable value.
PREVENTION
Unfortunately, in the majority of published cases, reasons as to why the error occurred were not fully investigated. In the other pediatric cases, multiple causes for error were often identified and these included: mistaking vincristine for intended IT medication [15-17, 22, 26, 28 ] mislabelling of syringes [18] , IV and IT drugs brought into treatment area at the same time [19, 22, 24] inexperienced medical staff administering medication [24, 27] , patient not treated in specialist unit [22, 24] , treatment given out of normal hours [24] and the administration order not checked [22, 28] .
Tragedies continue to occur despite over five decades of clinical experience with vincristine. Errors generally happen due to lapses in defensive barriers. Lapses occur for two reasons, termed active failures and latent conditions [40] . Active failures are unsafe acts committed by people directly in contact with the patient or system. Incorrect or inadequate drug labelling, intravenous vincristine being available in the intrathecal administration area and medical staff administering the drug by the wrong route are all examples of active failures. Latent conditions are inherent problems within the system that may lie dormant for many years before they combine with active failures and local triggers to produce an opportunity for error. Example of latent conditions that can transform into error provoking conditions include inexperienced or untrained medical staff involved in the use of chemotherapy, medication provided in an inappropriate form for administration, an unsuitable environment or time for intrathecal drug administration, and procedural problems such as the lack of doublechecking prior to drug administration by medical staff.
To prevent the possibility of accidental intrathecal administration of vincristine or other vinca alkaloids both the human and system failures that could occur need to be addressed. A number of specific recommendations have been made that warrant implementation (see Table 2 ). A number of these are specifically related to the preparation and administration of the drug and could be implemented very easily. Aspects associated with the training and authorization of hematology and medical oncology staff are more resource intensive and may require significant consultation and planning for implementation depending on local practices. The majority of cancer centers internationally have adopted these strategies and have employed them successfully for many years. A fatality has also occurred following the accidental intrathecal administration of vindesine despite immediate recognition and CSF washout [41] . Strategies for prevention must therefore address vincristine and all other vinca alkaloids including vinblastine, vindesine and vinorelbine.
Every error involving the administration of a vinca alkaloid into the spinal fluid over the past 45 years has occurred when the drug was prepared in a syringe [13] .
The safest and most effective approach for eliminating the potential spinal instillation of vincristine is therefore the abolishment of the syringe as a method of administration [42] . This strategy works on the premise that it would be virtually impossible to administer vincristine in this form to a patient via a spinal needle and also has the advantage of prompting staff to realise that something is obviously wrong if this is even attempted. Vincristine can be prepared in 50 mL of 0.9% sodium chloride and administered as a short IV bolus over 5 to 10 minutes. If necessary, a lesser volume of fluid and slower administration rate can be employed in younger children.
Concerns have been raised, particular by nursing groups, that this method may increase the risk of extravasation [43] . Extravasation rarely occurs (<1 per 1000 IV administrations) when proper approved techniques for antineoplastic drug administration are followed and the consequences are significantly less than those associated with the accidental intrathecal administration of vincristine [44] . Most extravasations can be prevented with the systematic implementation of careful, standardized, evidence-based administration techniques [45] . Preventative strategies include identification of patient-related and procedure-related risk factors, use of appropriate IV access devices (peripheral, central), thorough education of patients and administration by experienced trained and accredited nursing staff [45] [46] [47] . Many centers have advocated increasing the volume of diluent in the syringe as a deterrent to intrathecal vincristine administration, however, this is not a viable option as deaths have been reported following administration via a 10 mL [48] and 20 mL syringe [28] .
In a retrospective study of documented institutional case reports performed across 68 Australian hospitals, the incidence of extravasation of vinca alkaloids following administration via syringes and small volume infusion solutions was assessed [43] . The reported incidence of vincristine extravasation from syringes was 0.03% and 0.041% with small volume infusions. Data was obtained from 6 pediatric centers with no reported cases of extravasation from small volume infusions and 0.059% from syringes. Preliminary data from a prospective Saudi Arabian study, conducted in adults and children, reported no cases of extravasation in 200 patients during administration of vincristine in minibags [49] . Vincristine was administered via by both peripheral and central lines. This data further supports the recommendation to abolish the syringe as a means of drug delivery, with low volume, short infusion the safest method for the administration of vincristine. Vincristine and other vinca alkaloids should NOT be prepared and/or administered in syringes.
Vincristine and other vinca alkaloids should ONLY be prepared for administration in a small volume intravenous bag.
If possible, different delivery devices and connectors should be used for medications to be administered via the spinal and other parenteral routes.
All intrathecal drugs should be packaged separately and clearly labelled both on the syringe and outer container "For Intrathecal Use".
Vincristine and other vinca alkaloids should be clearly labelled both on the intravenous bag and outer container "For Intravenous Use OnlyFatal If Given By Other Routes".
Intrathecal drugs should be delivered to the administration area separately from drugs to be given by other routes.
Intrathecal drugs should only be given after drugs prescribed by other routes have been administered.
Intrathecal chemotherapy should only be administered in an area where no other antineoplastic drugs are accessible. Ideally, patients receiving antineoplastic medications by multiple routes should receive them in different practice areas or that these medications be administered on different days.
prepared in an intravenous syringe impossible to connect to a spinal needle [50] . Purpose built syringes or syringe caps for intrathecal drug delivery have also been suggested [51] . These could use printed text, shape and colour coding to designate specific use. A Canadian group have designed a spinal injection safety system (SISS) in which the special filling device is not compatible with existing needles and conversely medication placed in Luer lock syringes are not compatible with the SISS spinal needle [52] . The Department of Health in the United Kingdom has been evaluating prototype connector systems deemed incompatible with standard Luer equipment [53] . A simulation-based evaluation of two systems involving 59 experienced clinicians identified problems with two proposed alternatives to Luer devices [54] . Further modification has been necessary due to the possibility of cross-connectivity with Luer connectors, concerns about leakage and as some clinicians found the devices were not "user-friendly". While the development of innovative neuraxial connection devices is to be applauded they should only be used in conjunction with other proven strategies for prevention of intrathecal medication errors. Syringes of any type should never, under any circumstance, be used to administer vinca alkaloids as there is still the possibility, albeit small, of mistakenly using the wrong type of syringe during the manufacturing and dispensing process.
CONCLUSION
The consequences of accidental intrathecal administration of vincristine are devastating. This is especially upsetting as many of the reported fatalities have been in young patients with potentially curable malignancies. Currently no effective antidote for this dreadful error exists. Prompt recognition and immediate treatment with CSF drainage and exchange may be the only chance of influencing patient survival. Undoubtedly the best method of managing this problem is by developing effective methods of prevention and incorporating them as standard practice in oncology/hematology units in pediatric centers around the world. All health professionals must work with hospital administrators and government bodies to ensure that guidelines for prevention of this tragic error are universally adopted.
